EPCAT II tested whether extended aspirin is noninferior to rivaroxaban for preventing symptomatic venous thromboembolism after total hip or knee arthroplasty. Multicenter double-blind RCT of 3424 patients (1804 THA, 1620 TKA). All received rivaroxaban 10 mg through day 5, then continued it or switched to aspirin 81 mg (9 more days TKA, 30 days THA). Follow-up 90 days.
EPCAT II tested whether extended aspirin is noninferior to rivaroxaban for preventing symptomatic venous thromboembolism after total hip or knee arthroplasty. Multicenter double-blind RCT of 3424 patients (1804 THA, 1620 TKA). All received rivaroxaban 10 mg through day 5, then continued it or switched to aspirin 81 mg (9 more days TKA, 30 days THA). Follow-up 90 days.